Shares of Septerna, Inc. (NASDAQ:SEPN - Get Free Report) were up 6.4% during mid-day trading on Tuesday . The company traded as high as $23.10 and last traded at $23.07. Approximately 84,226 shares changed hands during trading, a decline of 60% from the average daily volume of 211,519 shares. The stock had previously closed at $21.69.
Analysts Set New Price Targets
A number of brokerages have weighed in on SEPN. TD Cowen started coverage on shares of Septerna in a report on Tuesday, November 19th. They issued a "buy" rating for the company. JPMorgan Chase & Co. began coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an "overweight" rating and a $38.00 price objective for the company. Cantor Fitzgerald began coverage on Septerna in a research note on Tuesday, November 19th. They set an "overweight" rating and a $50.00 price target on the stock. Finally, Wells Fargo & Company assumed coverage on Septerna in a report on Tuesday, November 19th. They issued an "overweight" rating and a $43.00 price target for the company.
Check Out Our Latest Research Report on SEPN
Septerna Price Performance
Insider Buying and Selling
In related news, major shareholder Rock Ventures V. L.P. Third purchased 370,500 shares of the stock in a transaction on Monday, October 28th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $6,669,000.00. Following the completion of the transaction, the insider now directly owns 6,215,591 shares of the company's stock, valued at approximately $111,880,638. The trade was a 6.34 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
About Septerna
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
Featured Articles
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
